ArticleDrug design, development and therapy2026
False Friends in Fluorescence - Simple HPLC Evaluation of False Positive Fragment Hits in a DiFMUP Assay for Protein Tyrosine Phosphatase 1B.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite their essential role in the reversible protein phosphorylation cycle governing cellular signaling and pathogenesis, phosphatases are frequently overlooked in drug development compared to protein kinases. Protein tyrosine phosphatase 1B (PTP1B) is a prominent therapeutic target due to its crucial role in the etiology of diabetes, obesity, and cancer. Consequently, the goal of this study was to identify fragments inhibiting PTP1B via the fluorogenic DiFMUP assay. Furthermore, we wanted to develop a method to evaluate our primary hits and identify optical artifacts associated with these standard fluorogenic screening assays. Methods: Utilizing the DiFMUP assay, we screened four fragment libraries against PTP1B. To identify false positives caused by spectral interference, the preliminary hits were evaluated through a fluorescence control experiment. Furthermore, we developed and validated a rapid HPLC method to directly quantify the substrate (DiFMUP) and product (DiFMU) for orthogonal verification independent of optical artifacts. Results: Our initial screening filtered 515 compounds down to 56 preliminary hits. The subsequent fluorescence control experiment revealed a high count of optically interfering fragments. Eventually, the direct quantification of DiFMUP and DiFMU by HPLC yielded three compounds demonstrating inhibition independent of optical interference. Conclusion: Our fragment screening identified three verified hits. Furthermore, we developed and validated a simple and rapid HPLC-based evaluation method. Although this orthogonal approach does not account for non-specific mechanisms like protein aggregation or oxidation, it serves as a highly useful tool to verify hits from fluorogenic assays. We propose the described screening and verification workflow as an efficient bridge between high-throughput optical assays and resource-intensive downstream testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.